Soligenix, Inc. — FY 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012; comparisons are to FY 2011. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. It had no significant product sales and relied principally on NIH grant revenue and prior-period licensing revenue.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $3.145 million | $7.663 million |
| Grant revenue | $3.145 million | $2.663 million |
| License revenue | None | $5.000 million |
| Gross profit | $0.552 million | $5.555 million |
| Research and development expense | $2.609 million | $6.273 million |
| General and administrative expense | $2.633 million | $2.242 million |
| Operating loss | $4.691 million | $2.960 million |
| Net loss | $4.163 million | $2.379 million |
| Basic and diluted loss per share | $0.37 | $0.22 |
| Cash used in operating activities | $2.636 million | $1.952 million |
- Revenue declined 59%, chiefly because FY 2011 included a one-time $5.0 million Sigma-Tau license payment. Gross profit fell by $5.003 million.
- R&D expense fell 58%, mainly because FY 2011 included costs for the orBec Phase 3 trial. G&A rose 17%, including $268,128 of non-cash charges associated with the rights reacquisition and accelerated option vesting.
- Cash and cash equivalents were $3.356 million at year-end, down from $5.997 million. Working capital was $2.682 million, down from $5.696 million. Total assets were $4.705 million and shareholders’ equity was $3.551 million.
- Current liabilities were $1.154 million, consisting principally of accounts payable and accrued compensation. The filing reports no debt balance. No meaningful product-sales margin or commercial operating margin was reported.
- Financing activities provided no cash in 2012; investing activities used $4,755. The company recognized a $521,458 tax benefit from selling New Jersey net operating loss carryforwards.
Material developments and outlook
- In December 2012, Soligenix acquired SGX94 technology, including related intellectual property and preclinical and Phase 1 data, and assumed an exclusive worldwide license from the University of British Columbia. SGX942, the finished product planned for oral mucositis, had FDA IND clearance; a Phase 2 trial was planned.
- Soligenix reacquired North American and European commercial rights to oral BDP from Sigma-Tau. The agreement includes potential approval and commercialization milestone payments up to $6 million, royalties on sales, and sharing of certain sublicense consideration. Related warrants and revised royalty terms with the oral BDP licensor were also disclosed.
- Management planned a Phase 1/2 SGX203 trial for pediatric Crohn’s disease in 2013. SGX201’s Phase 1/2 study for acute radiation enteritis was completed, with safety and preliminary efficacy signals reported; next steps remained under evaluation. A $300,000 NIH grant was awarded to support a Phase 2 chronic GI GVHD study of orBec.
- The orBec confirmatory Phase 3 trial in acute GI GVHD was stopped in 2011 on the independent monitoring board’s recommendation because it was highly unlikely to meet its efficacy endpoint; development for that indication was terminated. The filing reports no significant difference from placebo on the primary or prespecified secondary endpoints.
- RiVax’s Phase 1B study was completed in 2012; the filing reports safety and stronger neutralizing antibody levels with the alum-adjuvanted formulation. ThermoVax development was supported by a $9.4 million NIAID grant. OrbeShield showed improved survival in a canine GI-ARS study; Soligenix submitted a proposal for a potential BARDA contract in February 2013 and expected a response in the second half of 2013. VeloThrax remained preclinical.
- Management estimated cash would fund operations into the second quarter of 2014, based on cash on hand, grant proceeds, cost reductions, and expected New Jersey tax-program proceeds. It cited approximately $3.8 million of active grant funding still available, and forecast approximately $3.8 million of R&D spending over the next 12 months before reimbursements, offset by approximately $3.0 million of grant revenue. Additional financing may be needed; no assurance was given that it could be raised on favorable terms.
- Other key risks include clinical and regulatory failure, dependence on uncertain government grants and contracts, reliance on third-party manufacturers and licensors, competition, potential dilution, and limited cash runway. The company had 10 full-time employees at year-end. Its common stock traded OTCQB and was thinly traded.
Most important facts for investors to verify
- Whether the projected cash runway and planned financing needs remain consistent with actual cash burn, grant reimbursements, and New Jersey tax-program proceeds.
- Whether the planned SGX942 and SGX203 trials began on schedule, and the funding and clinical milestones required to advance them.
- Whether the BARDA proposal for OrbeShield received a contract award, and what funding, conditions, and development obligations it entails.
- The full economics and potential dilution associated with the Sigma-Tau rights reacquisition, including milestone and royalty obligations, sublicense sharing, and warrants.
- Whether grant funding is renewed or supplemented; grant-dependent revenue is not equivalent to recurring commercial product revenue.
- The status of outstanding options and warrants and the potential dilution they represent; the filing reported 2,843,338 warrants and 1,457,724 options outstanding at year-end.